Teleflex (NYSE:TFX) Cut to “Market Perform” at Citizens Jmp

Citizens Jmp downgraded shares of Teleflex (NYSE:TFX) from an outperform rating to a market perform rating in a research report sent to investors on Thursday, Marketbeat.com reports.

A number of other equities analysts have also recently issued reports on the stock. StockNews.com upgraded shares of Teleflex from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Mizuho dropped their price target on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada decreased their price objective on Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. Finally, Truist Financial cut their target price on Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $246.00.

Teleflex Trading Down 21.8 %

Shares of TFX opened at $138.99 on Thursday. The stock’s 50-day moving average price is $176.35 and its 200 day moving average price is $205.70. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $6.46 billion, a price-to-earnings ratio of 27.63, a P/E/G ratio of 1.73 and a beta of 1.16. Teleflex has a 12-month low of $135.95 and a 12-month high of $249.90.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. The business had revenue of $795.40 million for the quarter, compared to analysts’ expectations of $813.24 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. As a group, research analysts predict that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, March 7th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.98%. Teleflex’s dividend payout ratio (DPR) is currently 27.04%.

Institutional Investors Weigh In On Teleflex

A number of large investors have recently bought and sold shares of the business. Headlands Technologies LLC bought a new position in Teleflex in the 4th quarter valued at $29,000. Avior Wealth Management LLC increased its stake in shares of Teleflex by 190.6% in the third quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company’s stock valued at $38,000 after buying an additional 101 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Teleflex in the third quarter valued at about $40,000. True Wealth Design LLC lifted its position in Teleflex by 16,600.0% during the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company’s stock worth $41,000 after buying an additional 166 shares in the last quarter. Finally, Capital Performance Advisors LLP bought a new stake in Teleflex during the 3rd quarter worth about $54,000. 95.62% of the stock is currently owned by institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.